Further Studies of Attention Deficit Disorder - Residual Type (RT)

• Status: Completed
• Trial end date: 1994-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The first phase was a double-blind crossover design of methylphenidate in the treatment of adult ADHD. The second phase consisted of an open-label extension trial of methylphenidate in adult ADHD. It was hypothesized that methylphenidate would prove more effective than placebo in treating ADHD symptoms during the first phase. It was also hypothesized that methylphenidate responders from the double-blind trial would continue to benefit from treatment in the second phase. Improvement would include both ADHD symptoms and social adjustment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Utah
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Methylphenidate

Criteria

Inclusion Criteria:

• Ages 21-55 years; male and female; met "Utah Criteria" for adult ADHD; 95th or higher percentile on the Parent Rating Scale and/or the Wender Utah Rating Scale;

Exclusion Criteria:

• Patients with other axis-I and axis-II diagnoses were excluded as were patients with significant medical problems.